Eli Lilly and Company (LLY)vsWarby Parker Inc (WRBY)
LLY
Eli Lilly and Company
$1,372.99
+6.57%
HEALTHCARE · Cap: $1.12T
WRBY
Warby Parker Inc
$24.43
-2.55%
HEALTHCARE · Cap: $2.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 8639% more annual revenue ($79.67B vs $911.61M). LLY leads profitability with a 33.5% profit margin vs 0.8%. LLY trades at a lower P/E of 42.2x. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
WRBY
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-6.1%
Fair Value
$20.73
Current Price
$24.43
$3.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
No standout strengths identified
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
ROE of 0.4% — below average capital efficiency
0.8% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : WRBY
The primary concerns for WRBY are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 389.0x leaves little room for execution misses. Thin 0.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 1.90 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 30/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is an innovative direct-to-consumer eyewear company that has redefined the eyewear shopping experience since its inception in 2010. With a successful blend of e-commerce and physical retail expansion, the company offers stylish and affordable prescription glasses and sunglasses, appealing to a broad demographic. Warby Parker is distinguished by its commitment to social responsibility, exemplified by its "Buy a Pair, Give a Pair" initiative, which underscores its dedication to making a positive impact. As the company leverages its strong brand reputation and effective marketing strategies, it is well-positioned for continued growth in the increasingly competitive eyewear sector, addressing evolving consumer preferences while enhancing its social mission.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?